ChiCTR2600119737 版本V1.0 版本创建时间2026/03/03 11:07:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119737 

最近更新日期:

Date of Last Refreshed on:

2026-03-03 11:07:14 

注册时间:

Date of Registration:

2026-03-03 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于定量脑电分析阿尔茨海默病神经精神症状的机制研究

Public title:

Mechanistic Study of Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease Based on Quantitative Electroencephalography Analysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于定量脑电分析阿尔茨海默病精神行为症状的机制研究

Scientific title:

Mechanistic Study of Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease Based on Quantitative Electroencephalography Analysis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张立 

研究负责人:

张立 

Applicant:

Li Zhang 

Study leader:

Li Zhang 

申请注册联系人电话:

Applicant telephone:

+86 151 0822 5236

研究负责人电话:

Study leader's
telephone:

+86 151 0822 5236

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

541878451@qq.com

研究负责人电子邮件:

Study leader's E-mail:

541878451@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

成都市第四人民医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市金牛区互利西一巷8号

研究负责人通讯地址:

中国四川省成都市金牛区互利西一巷8号

Applicant address:

No. 8, Huli West 1st Lane, Yingmenkou, Jinniu District, Chengdu City, Sichuan Province, China

Study leader's address:

No. 8, Huli West 1st Lane, Yingmenkou, Jinniu District, Chengdu City, Sichuan Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都市第四人民医院

Applicant's institution:

Chengdu Fourth People's Hospital

研究负责人所在单位:

成都市第四人民医院

Affiliation of the Leader:

Chengdu Fourth People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2023]伦审字(46)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都市第四人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Fourth People's Hospital of Chengdu

伦理委员会批准日期:

Date of approved by ethic committee:

2023-12-25 00:00:00

伦理委员会联系人:

赵华昌

Contact Name of the ethic committee:

Huachang Zhao

伦理委员会联系地址:

中国四川省成都市金牛区互利西一巷8号

Contact Address of the ethic committee:

No. 8, Huli West 1st Lane, Yingmenkou, Jinniu District, Chengdu City, Sichuan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 130 9445 5990

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都市第四人民医院

Primary sponsor:

Chengdu Fourth People's Hospital

研究实施负责(组长)单位地址:

中国四川省成都市金牛区营门口互利西一巷8号

Primary sponsor's address:

No. 8, Huli West 1st Lane, Yingmenkou, Jinniu District, Chengdu City, Sichuan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都市第四人民医院

具体地址:

中国四川省成都市金牛区营门口互利西一巷8号

Institution
hospital:

Chengdu Fourth People's Hospital

Address:

No. 8, Huli West 1st Lane, Yingmenkou, Jinniu District, Chengdu City, Sichuan Province, China

经费或物资来源:

成都市医学科研项目(2023504)

Source(s) of funding:

Chengdu Medical Research Project(2023504)

研究疾病:

阿尔茨海默病  

Target disease:

alzheimer disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

了解定量脑电图分析在阿尔茨海默病(Alzheimer's disease,AD)患者精神行为症状(Behavioral and Psychological Symptoms of Dementia,BPSD)中的脑电模式,以探讨脑电图和阿尔茨海默病精神行为症状的相关性,为临床识别BPSD提供客观的生物依据。并确定脑电图参数是否可用于BPSD内部分组的临床评估。  

Objectives of Study:

Learning the manifestation of quantitative EEG analysis in Behavioral and psychological Symptoms of Dementia (BPSD) in patients with Alzheimer's disease (AD) is to explore the correlation between EEG and psychobehavioral symptoms of Alzheimer's disease,to provide objective biological basis for clinical identification of BPSD, and to determine whether EEG parameters can be used for clinical evaluation of BPSD internal grouping.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合美国精神病学会的精神统计手册修订第V版中AD的诊断标准; 2.年龄≥55岁; 3.自愿参与或经家属同意参与本次研究。

Inclusion criteria

1. Meets the diagnostic criteria for AD as stipulated in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association; 2. Age >= 55 years; 3. Voluntary participation or consent from the family members for this study.

排除标准:

1.排除存在严重心、肝、肾等重要器官疾病者; 2.排除能导致痴呆的全身性情况,如甲状腺功能减退、维生素B族或叶酸缺乏、烟酸缺乏、低钙血症、神经梅毒、HIV感染; 3.排除既往有精神障碍如抑郁、精神分裂症等所致认知功能障碍; 4.排除了服用胆碱酯酶抑制剂、苯二氮卓类或抗抑郁药物可能影响脑电图节律的患者; 5.排除近一月内服用了抗精神病药物治疗的患者; 6.排除不能完成检查者; 6.资料缺失20%及以上的问卷,作废处理。

Exclusion criteria:

1. Exclude individuals with severe diseases of vital organs such as the heart, liver, and kidneys. 2. Exclude systemic conditions that can cause dementia, including hypothyroidism, vitamin B complex or folic acid deficiency, niacin deficiency, hypocalcemia, neurosyphilis, and HIV infection. 3. Exclude patients with cognitive impairment caused by prior mental disorders such as depression and schizophrenia. 4. Exclude patients taking cholinesterase inhibitors, benzodiazepines, or antidepressants that may affect electroencephalogram (EEG) rhythms. 5. Exclude patients who received antipsychotic medication within the past month. 6. Exclude those unable to complete the examinations. 6. Questionnaires with 20% or more missing data shall be invalidated.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-02-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

AD伴BPSD症状组

样本量:

155

Group:

Group with BPSD symptoms in AD

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

AD不伴BPSD症状组

样本量:

100

Group:

Group without BPSD symptoms in AD

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

chengdu

单位(医院):

成都市第四人民医院 

单位级别:

三甲 

Institution
hospital:

Chengdu Fourth People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

神经精神症状量表(NPI)

指标类型:

主要指标

Outcome:

NeuroPsychiatyicInventory,NPI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易智力状态检查

指标类型:

主要指标

Outcome:

Mini-mental State Examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑电图定量指标(功率谱、网络属性)

指标类型:

主要指标

Outcome:

Eeg quantitative indicators (power spectrum, network attributes)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内侧颞叶萎缩视觉评分(MTA)

指标类型:

主要指标

Outcome:

Semiquantitative Visual Rating Scale for Medial Temporal Atrophy (MTA)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑白质病变半定量视觉评分(Fazekas 评分)

指标类型:

主要指标

Outcome:

Semiquantitative Visual Rating Scale for White Matter Lesions (Fazekas Scale)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 55 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开原始数据日期 本试验完成后 6 个月内 共享方式 接受符合研究伦理的研究者申请索取,联系人:张立,联系邮箱:541878451@qq.com,申请审核通过后提供完整原始数据(含定量脑电原始数据、病例报告表、研究相关元数据及数据说明文件)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date of Raw Data Public Release: Within 6 months after the completion of this studyData Sharing Method: The data are available upon request by researchers who conform to research ethics. Contact person: Zhang Li; Contact email: 541878451@qq.com. After the application is reviewed and approved, the complete raw data (including raw quantitative EEG data, case report forms, study-related metadata and data description files) will be provided.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-03-03 11:07:14